Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

PHASE3CompletedINTERVENTIONAL
Enrollment

665

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

April 29, 2016

Study Completion Date

April 29, 2016

Conditions
Opioid DependenceOpioid Related Disorders
Interventions
DRUG

SUBOXONE

SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.

DRUG

RBP-6000

Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.

DRUG

Placebo

Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.

Trial Locations (38)

16602

Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA, Altoona

19104

UPenn Treatment Research Center, Philadelphia

29407

Carolina Clinical Trials, Charleston

32256

Amit Vijapura, Jacksonville

32751

Florida Clinical Research Center, Maitland

Try Research, Maitland

33161

Scientific Clinical Research, North Miami

33319

Innovative Clinical Research, Lauderhill

33334

Research Centers of America, Oakland Park

35565

Haleyville Clinical Research, Haleyville

35570

Boyett Health Services, Hamilton

38805

Meridien Research, Lakeland

39232

Precise Research Centers, Inc., Flowood

44125

Charak Clinical Research Center, Garfield Heights

44718

Neuro-behavioral Clinical Research, Canton

45417

Midwest Clinical Research Center, Dayton

60194

Behavioral Health Care Associates, Schaumburg

63141

St Louis Clinical Trials, St Louis

66206

Phoenix Medical Research, Prairie Village

70114

Louisiana Research Associates, New Orleans

71101

Louisiana Clinical Research, Shreveport

72211

Woodland International Research Group, Little Rock

73112

Oklahoma Clinical Research Center, Oklahoma City

Pahl Pharmaceutical Professionals, Oklahoma City

75115

InSite Clinical Research, DeSoto

75243

Pillar Clinical Research, Dallas

89102

Altea Research, Las Vegas

91206

Behavioral Research Specialists, Glendale

91360

Southern California Research, Thousand Oaks

91950

Synergy Clinical Research Center, National City

92056

North County Clinical Research, Oceanside

92103

Artemis Institute for Clinical Research, San Diego

92845

Collaborative Neuroscience Network, Garden Grove

94103

Care Practice, San Francisco

97214

CODA, Portland

02720

Stanley Street Treatment and Resources, Fall River

02472

Adams Clinical Trials, Watertown

08009

Comprehensive Clinical Research, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02357901 - Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine | Biotech Hunter | Biotech Hunter